Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy
- PMID: 9307560
- PMCID: PMC1228113
Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy
Abstract
Objectives: To provide Canadian physicians with a standard definition of hypertension in pregnancy, recommendations for laboratory investigations and tests for the assessment and management of hypertensive disorders in pregnancy, and a classification of such disorders.
Options: To improve or not improve Canadian uniformity and standardization in the investigation and classification of hypertensive disorders in pregnancy.
Outcomes: 1) Accuracy, reliability and practicality of diagnostic clinical criteria for hypertensive disorders in pregnancy. 2) Laboratory tests useful to determine severity and prognosis of disorders as measured by maternal and neonatal adverse outcomes. 3) A classification of disorders for use by Canadian physicians to facilitate uniformity and diffusion of research through a common language.
Evidence: Articles on hypertensive disorders in pregnancy published from 1966 to 1996, retrieved through MEDLINE search, related to definitions, tests, diagnostic criteria and classification, as well as documents on diagnosis and classification from authorities in the United States, Europe and Australia and from special interest groups.
Values: High priority was given to the principle of preventing adverse maternal and neonatal outcomes through the provision of diagnostic criteria for severity and prognosis and through dissemination of reliable and pertinent information and research results using a common language. BENEFITS, HARMS AND COST: Higher degree of vigilance in diagnosing hypertensive disorders in pregnancy, allowing for earlier assessment and intervention, and more efficient dissemination of comparative information through common language. No harm or added cost is perceived at this time.
Recommendations: (1) A diastolic blood pressure of 90 mm Hg or more should be the criterion for a diagnosis of hypertension in pregnancy and should trigger investigation and management. Except for very high diastolic readings (110 mm Hg or more), all diastolic readings of 90 mm Hg or more should be confirmed after 4 hours. (2) A regularly calibrated mercury sphygmomanometer, with an appropriate-sized cuff, is the instrument of choice. A rest period of 10 minutes should be allowed before taking the blood pressure. The woman should be sitting upright and the cuff positioned at the level of the heart. (3) Both Korotkoff phase IV and V sounds should be recorded, but the phase IV sound should be used for initiating clinical investigation and management. (4) A urine protein level of more than 0.3 g/d should be the criterion for a diagnosis of proteinuria; 24-hour urine collection should be the standard method for determining proteinuria. (5) Edema and weight gain should not be used as diagnostic criteria. (6) Hypertensive disorders diagnosed during pregnancy should be classified as pre-existing hypertension; gestational hypertension with or without proteinuria; pre-existing hypertension with superimposed gestational hypertension with proteinuria; and unclassifiable antenatally but final classification 42 days after delivery.
Validation: Except for expert opinions and reviews solicited for this project, these recommendations need to be field tested and validated in Canada. Guidelines endorsed by the Canadian Hypertension Society and the Society of Obstetricians and Gynaecologists of Canada.
Comment in
-
Hypertension in pregnancy: new recommendations for management.CMAJ. 1997 Sep 15;157(6):709-10. CMAJ. 1997. PMID: 9307559 Free PMC article. No abstract available.
-
Which Korotkoff sound?CMAJ. 1998 Feb 10;158(3):297-8. CMAJ. 1998. PMID: 9484246 Free PMC article. No abstract available.
Similar articles
-
Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy.CMAJ. 1997 Oct 1;157(7):907-19. CMAJ. 1997. PMID: 9327800 Free PMC article. Review.
-
Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.CMAJ. 1997 Nov 1;157(9):1245-54. CMAJ. 1997. PMID: 9361646 Free PMC article. Review.
-
Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.CMAJ. 1999 May 4;160(9 Suppl):S1-6. CMAJ. 1999. PMID: 10333847 Free PMC article.
-
Lifestyle modifications to prevent and control hypertension. 3. Recommendations on alcohol consumption. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.CMAJ. 1999 May 4;160(9 Suppl):S13-20. CMAJ. 1999. PMID: 10333849 Free PMC article.
-
Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.CMAJ. 1999 May 4;160(9 Suppl):S29-34. CMAJ. 1999. PMID: 10333851 Free PMC article.
Cited by
-
Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.CMAJ. 1999;161 Suppl 12(12):S18-22. CMAJ. 1999. PMID: 10624418 Free PMC article.
-
Treating hypertension in women of child-bearing age and during pregnancy.Drug Saf. 2001;24(6):457-74. doi: 10.2165/00002018-200124060-00004. Drug Saf. 2001. PMID: 11368252 Review.
-
Diagnostic accuracy of random urinary protein-to-creatinine ratio for proteinuria in patients with suspected pre-eclampsia.Arch Gynecol Obstet. 2021 Jul;304(1):109-115. doi: 10.1007/s00404-020-05937-0. Epub 2021 Jan 1. Arch Gynecol Obstet. 2021. PMID: 33386413
-
Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia.PLoS One. 2017 Dec 22;12(12):e0189966. doi: 10.1371/journal.pone.0189966. eCollection 2017. PLoS One. 2017. PMID: 29272274 Free PMC article.
-
Angiotensin-converting enzyme I/D polymorphism and preeclampsia risk: evidence of small-study bias.PLoS Med. 2006 Dec;3(12):e520. doi: 10.1371/journal.pmed.0030520. PLoS Med. 2006. PMID: 17194198 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical